VCCircle’s Post

The outlook for #biotech IPOs is increasingly optimistic, including the following prediction shared at LSX World Congress. We have the expertise and the team to lead biotech companies through the entire #IPO journey. Contact Dan Dehner to start the conversation. https://lnkd.in/d6ZB_eF3

‘Next Wave of IPOs’ Will Arrive in Summer, Predicts Biotech-Focused VC Partner Delegates at the LSX World Conference in London seemed to agree on one thing—the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the initial run of public offerings died down by the spring. For Francesco De Rubertis, co-founder and partner of London-based life sciences investment firm Medicxi, the current lull is to be expected. What’s more, he expects “at least a number of IPOs” to arrive as soon as the summer. “In the absence of other external [factors], the natural dynamics of markets should say that now there will be another big number of investors that will become active on the public markets, and that will translate in the next wave of IPOs,” he told Fierce in an interview on the sidelines of the LSX conference. https://lnkd.in/d6ZB_eF3 #aspenalert #biotech #bioprocess

What a truly scintillating year it has been for block deals , especially by the private equity universe! In August, private equity major BPEA EQT sold 25 per cent stake for a whopping $893 mn in IT firm Coforge..and now this biggie in the pharma sector👇 According to our sources, a mega block deal is brewing in Mankind Pharma which galvanized the morbid Indian IPO market with a strong debut on the bourses in early May... Three private equity investors, ChrysCapital, Capital Group and Everbridge Partners are planning to sell 6.9 per cent stake ( around ₹592 mn) or 7.9 per cent stake ( $677 mn) in the top pharma company depending on whether the base or up size option is used... More deal details in the story below :

...It’s obviously still extremely early in the game, but each piece of the emerging puzzle is being studied with medieval devotion to discern what will happen through the rest of the year for biotech....The fourth-quarter thaw we saw toward the end of last year on the XBI has led to more solid green shoots of a biotech spring, underscoring that the yearned-for recovery is off to a start. And that’s incredibly important. IPO money — and the follow-ons to come — can encourage VCs that have been hunkering down for the winter, focused on streamlining their portfolio companies. It’s a source of billions of dollars that can reverse some worrisome trends at CDMOs, CROs and other suppliers. And it offers bankers a chance to get back in the game after sitting on the sidelines in a post-boom funk..... #IPO #funding #investments #venturecapital #VC #biotech #biotechnology #biotechnologyindustry #CDMO #contractmanufacturing #publicmarkets #signsofrecovery #followonfunding #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #lifesciences #healthcare #trending #recovery #financing #fuelingsuccess

2023 ended on a high note for biotech, with positive signs like the XBI rebounding over 30% from its lows and potential rate cuts on the horizon for 2024. Is the improved sentiment sustainable? Late last year, ENTENTE CEO Virginia Amann spoke with industry veterans Gabriel Cavazos, Marian Nakada, Ph.D., Dennis Purcell and Brad Sitko at a salon hosted by Demy-Colton find out.   The discussion revolves around the challenges faced by biotech CEOs in a slow IPO market, exploring various financing strategies and the importance of strategic planning.    Read the full story in ENMEDIA, part of our JPM Week series. Link in comments.   #biotech #finance #venturecapital #innovation #jpmhc24

One of the greatest things about being an individual biotech investor is that you don't have to have insider access or special friends at Venture Capital funds In order to invest in embryonic, very early stage biotech firms. In today's public market, there are many fledgling biotech companies that are years away from having a viable product. There's even a few public companies that don't even have viable products in clinical testing yet. Just a few collection of good molecules and hopeful prayers. If you have a taste for risk and you want to get in on the latest innovations before they're even profitable, check out names that make up the exchange traded fund XBI. You'll save a bundle on fees, enjoy more liquidity and more transparency than investing in a VC fund but the effect will basically be the same. These are very young companies. #Biotech #Biotechnology #Wallstreet

Private equity and venture capital success stories in healthcare 🏆   On Rare Disease Day, find out how the asset class supports healthcare and biotech businesses across Europe, supporting their development of novel treatments.   Filter by sector, country or type of investor ⤵️   ➡️ https://lnkd.in/ec3A-mrA   #InvestEurope #PrivateEquity #VentureCapital #BuildingBetterBusinesses #SuccessStories #RareDiseaseDay

John Carroll and Chris Dokomajilar present a cautious optimism in the Endpoints News article for the life sciences / biotech sector this year, emphasizing a potential rebound in mergers and acquisitions (M&A), initial public offerings (IPOs), and venture funding. Following a slump, there's a significant uptick in M&A activity in Q4 2023, driven by Big Pharma's strategic acquisitions to fill pipeline gaps, suggesting a trend towards smaller, strategic deals continuing into 2024. IPO activity is hinted at possibly regaining momentum, with examples of successful early IPOs inspiring confidence,e.g., CG Oncology. Venture funding, however, faced a tough period, with investments cratering but showing signs of stabilization and potential recovery as investors adjust to a post-boom environment, looking towards M&A and IPOs for liquidity and growth opportunities. Hoping for rate cuts by the Fed. Yesterday did not help. Hopefully, March will be a different outcome. But more likely May/ June. Buckle up! #biotechnology #venturecapital #mergersandacquisitions

As the first quarter of 2024 is coming to a close, it's shaping up to be an exciting year in biotech and biopharma. A few reasons for optimism (with references you should really check out yourself): 💰 • Investment has picked up, specifically with series A and series B rounds of funding. With a shift in focus on delivering tangible value rather than futures, investors are clearly more bullish on new investment. https://lnkd.in/gB3cdUP7 📊 • M&A activity (and strategic partnerships) has also seen an uptick to start the year, right on the heals of a strong 2023 Q4. https://lnkd.in/gsPrNCpi 📈 • While we saw a slow down in March, IPO activity has also been strong to start the year - stronger than at any point since 2021. Certainly something to keep an eye on, and prepare for, as we head deeper into the year. https://lnkd.in/gJxn-gEG https://lnkd.in/gbFJyBva Now is the time to ensure your organization is in position to fully capitalize on a very exciting time for biotech and life sciences.

🧬 European Life Sciences deals overview for 2023 & 2024 outlook 📈 https://lnkd.in/dsiQ5NpB Excited to share our latest publication. In this report, we delve into the dynamic landscape of life sciences investments across European targets, highlighting key trends across each deal type, notable deals, and emerging opportunities shaping the industry Explore the full report to stay informed and gain strategic perspectives on the future of life sciences investments in Europe #LifeSciences #Biotech #Investments